| Parameter | RTS,S/AS01 trial | Primaquine trial | PfSPZ Vaccine trial |
---|---|---|---|---|
Infection rates observed in each trial | Proportion of controls infected during follow-up | 0.39 | 0.71 | 0.56 |
Proportion of subjects in treatment arm infected during follow-up | 0.26 | 0.28 | 0.36 | |
Inputs to simulation study | Exposure rate | 1/741 | 1/182 | 1/204 |
Clone blocking probability | 0.61 | 0.80 | 0.76 | |
Mean number of clones at first infection in control group | 2.26 | 1.46 | 3.00 | |
Follow-up duration | 12Â months (364Â days) | 8Â months (224Â days) | 6Â months (168Â days) |